Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: April 2015

2 - Sepsis, severe sepsis, and septic shock

from Part I - Clinical syndromes: general

Summary

DEFINITIONS

Sepsis is a complex syndrome that results from a host's response to infection. Simply put, it is the systemic inflammatory response syndrome (SIRS) arising because of documented or suspected infection. Clinically, SIRS is identified by the presence of at least two of the following: fever or hypothermia, tachycardia, tachypnea, and leukocytosis or leukopenia. Severe sepsis is sepsis with organ dysfunction or tissue hypoperfusion from the infection. Septic shock is severe sepsis plus hypotension that is not corrected by fluid resuscitation. Since 1991, the definitions and diagnostic criteria have expanded with inflammatory, hemodynamic, organ dysfunction, and tissue perfusion variables, but general definitions are the same. Sepsis-related terminology and definitions are in Table 2.1. Diagnostic criteria for sepsis are in Table 2.2. The document by a consensus committee of international experts called “Surviving Sepsis Campaign” has become one of the most comprehensive guidelines for clinicians as to best practice (though not yet standard of care) in the care of patients with severe sepsis and septic shock.

EPIDEMIOLOGY

The incidence of sepsis, severe sepsis, and septic shock are probably underestimated since most estimates are based on hospital databases that rely on the International Classification of Diseases, and so are biased toward a more severely ill population. The global incidence of sepsis is reported as from 22 to 240 cases/100 000 persons; severe sepsis from 13 to 300 cases/100 000 persons; and for septic shock, 11 cases/100 000 persons (based on a 2012 study). Case-fatality rates are as high as 30% for sepsis, 50% for severe sepsis, and 80% for septic shock. In the United States, the incidence of severe sepsis had been rising but in-hospital mortality was decreasing and not significantly different from Europe.

Related content

Powered by UNSILO
Suggested reading
Dellinger, RP, Levy, MM, Rhodes, A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41–2:580–637.
Hotchkiss, RS, Monneret, G, Payen, D. Immunosuppression in sepsis: a novel understanding and a new therapeutic approach. Lancet Infect Dis. 2013;13:260–268.
Jawad, I, Luksic, I, Rafnsson, SB.Assessing available information of the burden of sepsis: global estimates of incidence, prevalence and mortality. J Glob Health. 2012;2–1:1–9.
Kumar, A, Roberts, D, Wood, KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34–6:1589–1596.
Lelubre, C, Vincent, J.Red blood cell transfusion in the critically ill patient. Ann Intensive Care. 2011;1:43.
MacArthur, RD, Miller, M, Albertson, T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2004;38:284–288.
Munford, RS, Suffredini, AF. Sepsis, severe sepsis, and septic shock. In: Mandell, GL, Bennett, JE, Dolin, R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th edn. Philadelphia: Churchill Livingstone; 2010:987–1010.
Nduka, OO, Parrillo, JE.The pathophysiology of septic shock. Crit Care Clin. 2009;25:677–702.
Ranieri, VM, Thompson, BT, Barie, PS, et al. Drotecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055–2064.
Reddy, RC, Standiford, TJ.Effects of sepsis on neutrophil chemotaxis. Curr Opin Hematol. 2010;17:18–24.
Sprung, CL, Annane, D, Keh, D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111–124.